Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-204274
Filing Date
2026-05-04
Accepted
2026-05-04 17:04:24
Documents
92
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q axsm-20260331.htm   iXBRL 10-Q 2688034
2 EX-31.1 axsm-ex31_1.htm EX-31.1 16863
3 EX-31.2 axsm-ex31_2.htm EX-31.2 16747
4 EX-32.1 axsm-ex32_1.htm EX-32.1 8174
5 EX-32.2 axsm-ex32_2.htm EX-32.2 8152
  Complete submission text file 0001193125-26-204274.txt   11686565

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT axsm-20260331.xsd EX-101.SCH 1689482
96 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20260331_htm.xml XML 2079310
Mailing Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37635 | Film No.: 26938890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)